Galapagos FIRST LOOK: ATALANTA-1 to kick off in the US
Galapagos has obtained IND clearance to initiate its ATALANTA-1 study with GLPG5101 for r/r NHL in the US. The study is already ongoing in Europe, and Galapagos recently presented encouraging data at EHA with solid outcomes generally in line with Yescarta and outperforming in FL. Looking ahead, we anticipate additional data from Galapagos' CAR-T programs (likely at ASH) could provide further validation as the dataset matures. We reiterate our € 50 TP and Buy rating.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.